SCHEMBL21570183

SCHEMBL21570183

O=C(O)c1cc2n(c1)CCCC(O)C2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.36
GAA P10253 5/20 0.32
KDM4E B2RXH2 4/20 0.32
HSD17B10 Q99714 3/20 0.32
POLB P06746 2/20 0.32
NR4A1 P22736 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
KDM4C Q9H3R0 3/20 0.32
MEN1 O00255 2/20 0.32
ALDH1A1 P00352 2/20 0.32
KMT2A Q03164 2/20 0.32
L3MBTL3 Q96JM7 1/20 0.31
HPGD P15428 1/20 0.31
USP2 O75604 1/20 0.30
KMO O15229 1/20 0.30
MAPT P10636 1/20 0.30
ITGB3 P05106 1/20 0.30
ITGA2B P08514 1/20 0.30
DRD3 P35462 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21570140 0.90 HDAC6 (0.35) HDAC6GAAKDM4EHSD17B10POLB
SCHEMBL26085556 0.83 USP2 (0.42) HDAC6GAAKDM4EHSD17B10POLB
SCHEMBL21570229 0.82 HSD17B10 (0.42) HDAC6KDM4EHSD17B10L3MBTL1ALDH1A1
SCHEMBL21570180 0.80 KMT2A (0.36) HDAC6GAAKDM4EHSD17B10POLB
SCHEMBL21570231 0.78 ALDH1A1 (0.37) HDAC6GAAKDM4EHSD17B10POLB
SCHEMBL26085552 0.76 USP2 (0.47) HDAC6GAAKDM4EHSD17B10POLB
SCHEMBL1393022 0.75 ALDH1A1 (0.39) HDAC6GAAKDM4EHSD17B10POLB
SCHEMBL21570216 0.73 PTGER4 (0.36) HDAC6GAAKDM4EHSD17B10POLB
SCHEMBL21570137 0.73 KDM4E (0.39) HDAC6GAAKDM4EHSD17B10POLB
SCHEMBL28498863 0.71 ALDH1A1 (0.36) HDAC6GAAKDM4EHSD17B10POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4029868-B1 MCL-1 INHIBITORS GILEAD SCIENCES INC (US) 2026-05-20 EP disclosed
CN-117304130-A MCL-1 inhibitors 吉利德科学公司 2023-12-29 CN disclosed
US-20230312490-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2023-10-05 US disclosed
CN-112118845-B MCL-1 inhibitors 吉利德科学公司 2023-06-13 CN disclosed
US-11643400-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2023-05-09 US disclosed
US-20220340535-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2022-10-27 US disclosed
EP-4029868-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. (US) 2022-07-20 EP disclosed
US-10988451-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2021-04-27 US disclosed
EP-3793565-A1 MCL-1 INHIBITORS Gilead Sciences, Inc. (US) 2021-03-24 EP disclosed
CN-112118845-A MCL-1 inhibitors 吉利德科学公司 2020-12-22 CN disclosed
US-20200331870-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2020-10-22 US disclosed
US-10703733-B2 MCL-1 inhibitors GILEAD SCIENCES, INC. (US) 2020-07-07 US disclosed
US-20190352271-A1 MCL-1 INHIBITORS GILEAD SCIENCES, INC. 2019-11-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190352271-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 HDAC6 178/4885GAA 2577/4885KDM4E 2079/4885
US-20200331870-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 HDAC6 178/4885GAA 2577/4885KDM4E 2079/4885
US-20230312490-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 HDAC6 178/4885GAA 2577/4885KDM4E 2079/4885
US-10703733-B2 MCL-1 inhibitors MCL1, BCL2L1, BCL2 HDAC6 178/4885GAA 2577/4885KDM4E 2079/4885
US-11643400-B2 MCL-1 inhibitors MCL1, BCL2L1, BCL2 HDAC6 178/4885GAA 2577/4885KDM4E 2079/4885
US-10988451-B2 MCL-1 inhibitors MCL1, BCL2L1, BCL2 HDAC6 178/4885GAA 2577/4885KDM4E 2079/4885
US-20220340535-A1 MCL-1 INHIBITORS MCL1, BCL2L1, BCL2 HDAC6 178/4885GAA 2577/4885KDM4E 2079/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.